CPIX CUMBERLAND PHARMACEUTICALS INC
Pharmaceutical Preparations · Nasdaq · SEC CIK 1087294 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY10.7%
TTM net income YoY2,167.1%
TTM EPS YoY1,962.5%
Revenue 3-yr CAGR-13.9%
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin-38.2%
Net margin273.7%
FCF margin-3.9%
EBITDA margin-33.6%
Returns
ROE139.5%
ROA76.6%
ROIC (approx.)-532.4%
Asset turnover0.28x
Leverage & solvency
Liabilities / assets36.6%
Debt / equity0.00x
Current ratio3.05x
Interest coverage-47.02x
Cash quality & payout
Operating cash flow / net income-0.01x
Accruals ratio77.6%
Payout ratio—
Capex / revenue0.2%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 | FY20232023-12-31 | FY20222022-12-31 | FY20212021-12-31 |
|---|---|---|---|---|---|
| Income statement | |||||
| Revenue | $44.52M | $37.87M | $39.55M | $42.01M | $35.99M |
| Cost of revenue | $6.67M | $6.59M | $6.07M | $9.12M | $8.81M |
| Gross profit | $37.85M | $31.28M | $33.49M | $32.89M | $27.17M |
| R&D expense | $5.57M | $4.82M | $5.83M | $6.69M | $5.68M |
| SG&A expense | $11.95M | $11.13M | $10.65M | $10.18M | $9.78M |
| Operating income | -$2.79M | -$6.43M | -$9.55M | -$5.70M | -$7.68M |
| Interest expense | $495,990 | $605,508 | $667,861 | $585,995 | $98,031 |
| Pretax income | -$2.81M | -$6.47M | -$6.28M | -$5.58M | -$5.56M |
| Income tax | $40,256 | -$22,669 | $45,769 | $68,850 | $34,891 |
| Net income | -$2.84M | -$6.48M | -$6.28M | -$5.57M | -$3.51M |
| EBITDA | $1.35M | -$1.53M | -$4.62M | -$376,816 | -$3.07M |
| EPS (basic) | -0.19 | -0.46 | -0.44 | -0.38 | -0.24 |
| EPS (diluted) | -0.19 | -0.46 | -0.44 | -0.38 | -0.24 |
| Weighted avg. shares (diluted) | 14.85M | 14.06M | 14.30M | 14.56M | 14.90M |
| Balance sheet | |||||
| Cash & equivalents | $11.44M | $17.96M | $18.32M | $19.76M | $27.04M |
| Receivables | $16.94M | $11.70M | $9.76M | $13.16M | $6.88M |
| Inventory | $29,935 | $4.00M | $4.61M | $9.86M | $8.43M |
| Current assets | $37.06M | $36.45M | $35.71M | $45.87M | $45.69M |
| PP&E, net | $264,724 | $277,365 | $367,903 | $284,039 | $442,635 |
| Goodwill | $914,000 | $914,000 | $914,000 | $914,000 | $882,000 |
| Intangibles | $53,621 | $17.97M | $22.61M | $30.59M | $23.95M |
| Total assets | $76.82M | $75.58M | $81.78M | $92.93M | $84.46M |
| Current liabilities | $36.74M | $31.62M | $27.98M | $28.58M | $19.28M |
| Short-term debt | $0 | $5.10M | $0 | — | — |
| Total liabilities | $52.28M | $53.04M | $52.52M | $56.95M | $41.86M |
| Shareholders' equity | $24.88M | $22.85M | $29.60M | $36.27M | $42.81M |
| Shares outstanding | 14.96M | 13.95M | 14.12M | 14.37M | 14.74M |
| Cash flow statement | |||||
| Operating cash flow | $4.93M | -$612,186 | $6.09M | $8.45M | $6.34M |
| Capital expenditure | $97,903 | $66,461 | $281,268 | $102,148 | $103,532 |
| Free cash flow | $4.83M | -$678,647 | $5.81M | $8.35M | $6.24M |
| Investing cash flow | -$4.71M | $57,842 | -$105,695 | -$13.67M | -$501,893 |
| Financing cash flow | -$6.75M | $196,904 | -$7.42M | -$2.06M | -$3.55M |
| Depreciation & amortization | $4.15M | $4.90M | $4.94M | $5.33M | $4.61M |
| Stock-based compensation | $408,320 | $301,895 | $365,040 | $447,503 | $741,867 |
| Share buybacks | $263,478 | $579,049 | $740,533 | $1.05M | $1.39M |
Free plan shows the latest 5 periods; Pro shows all 17 🔒
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.